Travere Therapeutics, Inc.
NASDAQ:TVTX
Overview | Financials
Company Name | Travere Therapeutics, Inc. |
Symbol | TVTX |
Currency | USD |
Price | 21.1 |
Market Cap | 1,836,423,730 |
Dividend Yield | 0% |
52-week-range | 5.12 - 21.56 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Eric M. Dube Ph.D. |
Website | https://www.travere.com |
An error occurred while fetching data.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD